mAbxience Research

mAbxience is a global biopharmaceutical company specializing in the development, manufacture, and commercialization of biosimilar monoclonal antibodies. Established in 2010, the company operates state-of-the-art facilities in Spain and Argentina, utilizing advanced single-use bioreactor technology to ensure high-quality and cost-effective production. In addition to its robust internal pipeline of biosimilars for oncology, immunology, and ophthalmology, mAbxience provides comprehensive Contract Development and Manufacturing Organization (CDMO) services to global partners. The company is currently a majority-owned subsidiary of Fresenius Kabi, following a strategic acquisition in 2022 that integrated it into a global healthcare network.